NDAORALTABLET
Approved
Jun 2003
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
4/8 — Partial
STALEVO 150 (carbidopa, levodopa, and entacapone) by Orion Pharma is catechol o-methyltransferase inhibitors [moa]. Approved for catechol-o-methyltransferase inhibitor [epc]. First approved in 2003.
Drug data last refreshed 10h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
STALEVO 150 is a fixed-dose combination tablet containing carbidopa, levodopa, and entacapone, approved in 2003 for Parkinson's disease. It works by combining a dopamine precursor (levodopa) with a decarboxylase inhibitor (carbidopa) and a catechol-O-methyltransferase (COMT) inhibitor (entacapone) to extend dopaminergic activity and reduce motor fluctuations. This triple combination improves treatment efficacy by maintaining more stable dopamine levels in the brain.
$0.127MPart D
LOE ApproachingDeclining
Product is approaching loss of exclusivity with modest Part D spending (~$127K in 2023), indicating a contracting commercial opportunity and potential team consolidation.
Mechanism of Action
Catechol O-Methyltransferase Inhibitors
Pharmacologic Class:
Catechol-O-Methyltransferase Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on STALEVO 150 offers limited career growth given its LOE-approaching lifecycle and minimal current hiring (0 linked jobs). Roles would focus on managed decline, market access negotiation, and authorized generic transition rather than growth-stage commercial execution.
Brand ManagerProduct Manager
Worked on STALEVO 150 at Orion Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.